USCOM LIMITED — Interim / Quarterly Report 2015

Feb 25, 2015

==> picture [62 x 459] intentionally omitted <==

( ASX

-­‐
UCM ) Uscom
Limited FY
2015
Half
Yearly
Results Thursday
26
January
2015

Premium Cardiovascular Medical Devices

Saving lives and Improving care Dr
Rob
Phillips PhD(Med),
MPhil(Med),
FASE,
DMU(Cardiol) ExecuHve
Chairman,
Chief
ExecuHve
Officer,
Head
Clinical
Science The Measure of Life

www.uscom.com.au

==> picture [69 x 81] intentionally omitted <==

1

==> picture [62 x 459] intentionally omitted <==

2015 Half Year Results

Call In Briefing Details

12pm. AEDT, Thursday, 26th February, 2015

Accessing via Telephone: Please dial in five minutes prior to the start of the call and provide the pin number 3175198.

Regional dial- in numbers are as follows: Sydney: 02 9007 4041 Melbourne: 03 9912 0327 Brisbane: 07 3107 0200 Australia: toll-free 1800 556264 International: +61 2 9007 4041

==> picture [69 x 81] intentionally omitted <==

2

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

2015 Half Year Results

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Uscom (the "Company”). While Uscom has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

www.uscom.com.au

3

==> picture [62 x 459] intentionally omitted <==

2015 Half Year Results

• Results

• Summary

• Financials – year on year, and 3yr growth

• Operations – distribution growth

• Investment growth

• Future growth – strategies and prospects

• Questions

==> picture [69 x 81] intentionally omitted <==

4

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Results - Summary

Half Year FY 2015

• Revenue up 147% to $0.96m from $0.39m

• Sales up 125% to $0.84m from $0.37m

• Net loss down 40% to $0.39m from $0.65m

• Cash on hand $1m 31 December 2014

• Approaching profitability

==> picture [69 x 81] intentionally omitted <==

5

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Financial Growth

==> picture [542 x 321] intentionally omitted <==

----- Start of picture text -----

Growth H1 2015
1200000
+147%
1000000 +125% 956886
+121% 835449
800000
722481
2013 H1
600000
2014 H1
387119
371808
400000
327109
200000
0
Receipts Sales Revenue Revenue
----- End of picture text -----

year on year

www.uscom.com.au

==> picture [69 x 81] intentionally omitted <==

6

==> picture [738 x 459] intentionally omitted <==

----- Start of picture text -----

Financial Growth
Quarterly Sales Revenue Quarterly Receipts
600000 500000
450000
500000
400000
350000
400000
300000
$ 300000 $ 250000
200000
200000
150000
100000
100000
50000
0 0
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
2013 2013 2013 2013 2014 2014 2014 2014 2015 2015 2013 2013 2013 2013 2014 2014 2014 2014 2015 2015
----- End of picture text -----

Three year

==> picture [69 x 81] intentionally omitted <==

7

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Operations - Milestones

Half Year FY 2015

• Chinese FDA registration for the USCOM 1A

• Distributors increased by 30% (27 to 35)

• New management appointments - distribution + sales

• First commercial BP+ manufacture

• Johnson & Johnson AusBiotech Company of the Year

• USCOM sold into the Russian Federal Space Agency

==> picture [69 x 81] intentionally omitted <==

8

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Operations - Growth

Distribution Agreements

==> picture [385 x 230] intentionally omitted <==

----- Start of picture text -----

40
35
35
+30%
30
27
25
+125%
20
15
12
10
5
0
2013 2014 2015
----- End of picture text -----*

Growing distribution, grows revenue

==> picture [78 x 12] intentionally omitted <==

----- Start of picture text -----

* FY to date
----- End of picture text -----

==> picture [69 x 81] intentionally omitted <==

9

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Investment – Growth

==> picture [433 x 282] intentionally omitted <==

----- Start of picture text -----

Uscom Share Price
25
22
20
15
15
10.5
10
6.7
5
0
Jan-12 2012 vwap 2013 vwap 2014 vwap
$ x 100
----- End of picture text -----

Future driven by;

China FDA approval – future revenue growth Impact of BP+ acquisition and marketing Increasing sales and operational strength

==> picture [69 x 81] intentionally omitted <==

10

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

Future Growth

Poised for growth

• Chinese FDA Uscom BP+ registration and revenue

• New distributors achieve aggressive revenue targets

• Volume manufacture led by demand

• New partnerships with distributors of scale and reach

• Incremental strategic growth opportunities

• Profitability, globalised operations

==> picture [69 x 81] intentionally omitted <==

11

www.uscom.com.au

==> picture [62 x 459] intentionally omitted <==

( ASX

-­‐
UCM ) Uscom
Limited FY
2015
Half
Yearly
Results Thursday
26
January
2015

Thank You Questions and Discussion

Dr
Rob
Phillips PhD(Med),
MPhil(Med),
FASE,
DMU(Cardiol) ExecuHve
Chairman,
Chief
ExecuHve
Officer,
Head
Clinical
Science

==> picture [69 x 81] intentionally omitted <==

The Measure of Life

www.uscom.com.au